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S U M M A R Y
Background: Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms. Cystic
ﬁbrosis (CF) patients are susceptible to NTM, but data about NTM in patients with non-CF bronchiectasis
are limited.
Methods: We conducted a retrospective, descriptive study at the University of Illinois Medical Center. All
patients diagnosed with bronchiectasis (code 494) using the International Classiﬁcation of Diseases,
ninth revision (ICD-9), between 1999 and 2006, were identiﬁed. Clinical data including lung function,
radiology studies, and presence of NTM in sputum were abstracted for those who met the study criteria.
Results: One hundred eighty-two patients were enrolled in the study. Patients were divided into two
groups: bronchiectasis with NTM isolates (n = 68) and bronchiectasis without isolates (n =114), and
compared for clinical characteristics and underlying diseases. Mycobacterium avium complex (MAC) was
the most common isolate. Fifty-ﬁve patients (30%) met the American Thoracic Society criteria for
diagnosis of NTM disease. Gram-negative rods were commonly co-isolated. The probability of NTM
isolation was signiﬁcantly higher in elderly female patients (p = 0.04). Moreover, the probability of NTM
isolation was signiﬁcantly higher in the female group with low body mass index (BMI) (p = 0.002).
Conclusions: NTM infections are common in non-CF bronchiectasis. MAC is the most frequently isolated
NTM in these patients. There is also great variability in age and sex characteristics for NTM in non-CF
bronchiectasis patients. Female patients with a low BMI are a high risk group for NTM infection in non-CF
bronchiectasis. Routine screening for NTM is strongly recommended in this patient population.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Bronchiectasis represents a signiﬁcant disease entity that has
been historically under-represented in the medical literature.1
Bronchiectasis is a disease of the bronchi and bronchioles involving
a vicious circle of transmural infection and inﬂammation with
mediator release. Bronchiectasis in general can manifest in one of
two forms: as a local or focal obstructive process of a segment or
lobe of a lung, or as a diffuse process involving most of the lungs.2
When extensive, bronchiectasis has the potential to cause
devastating illness by predisposing susceptible individuals to
recurrent respiratory infections. While the lower respiratory tract
is normally sterile, conditions such as bronchiectasis enable
colonization of a variety of microbes. Recent advances in molecular
technology have led to the unprecedented ability to analyze* Corresponding author. Tel.: +1 312 996 8039; fax: +1 312 996 4665.
E-mail address: rtsadikot@uﬂ.edu (R.T. Sadikot).
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http://dx.doi.org/10.1016/j.ijid.2013.03.018complex microbial populations, revealing extensive communities
of often unculturable or previously unidentiﬁed organisms.3,4
Recently, the incidence of non-tuberculous mycobacterial (NTM)
infections has been increasingly reported both in the immunocom-
promised and immunocompetent population. Pulmonary infections
with bronchiectasis due to NTM are also increasing in incidence
worldwide.5,6 Much of this increase in incidence is likely due to
advancements in diagnostic techniques such as high-resolution
computed tomography (HRCT). HRCT has proved to be a reliable and
non-invasive method for the diagnosis of bronchiectasis. The pattern
and distribution of abnormalities revealed by HRCT scanning are
inﬂuenced by the underlying cause of bronchiectasis.7 Multiple
small nodules, along with the occasional appearance of one or more
cavities combined with diffuse bronchiectasis are reported to be the
typical HRCT ﬁndings of NTM pulmonary infection associated with
bronchiectasis.8 In patients with characteristic HRCT ﬁndings, 34–
50% of patients have an active NTM pulmonary infection. The
etiologies of NTM infections are also being identiﬁed more readily
with improvements in laboratory methodology, liquid culturenal Society for Infectious Diseases.
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organism associated with these infections is Mycobacterium avium
complex infection.9
Despite these advances in diagnostics, the diagnosis of NTM
pulmonary infection is still often delayed because symptoms are
mild and excretion of NTM in sputum is intermittent with few
colonies retrievable in culture. Many patients therefore require
bronchoscopic examination or a lung biopsy for diagnosis of NTM
pulmonary disease.10 Because there is limited information about
characteristics of dual diseases of NTM and bronchiectasis, this
study evaluated a cohort of patients with adult-onset bronchiec-
tasis to determine the prevalence of NTM in this group. Clinical
indices were also compared with patients with bronchiectasis who
did not grow NTM to determine whether there was any association
with disease severity, antibiotic usage, radiographic changes, or
microbiology.
2. Methods
The study was performed at the University of Illinois Medical
Center. A retrospective chart review was conducted after obtaining
approval from the Internal Review Board (IRB). All patients
diagnosed with bronchiectasis (code 494) using the International
Classiﬁcation of Diseases, ninth revision (ICD-9), between 1999
and 2006, were identiﬁed. Consent was waived because of the
retrospective nature of the study. A list of 306 patients with ICD
code 494 was generated. Patients were included in the study if they
were aged 18 years or older, with conﬁrmed radiological changes
suggestive of bronchiectasis on chest X-ray or CT scan of the chest
reported by a radiologist, which was independently evaluated by
two clinicians (Figure 1). The radiological criteria used to deﬁne
bronchiectasis included: bronchial dilation (bronchial diameter
compared to adjacent to pulmonary artery), peri-bronchial wall
thickening, and cylindrical changes. Patients with known cystic
ﬁbrosis (CF) were excluded (n = 6). The investigation for CF was
performed based on clinical suspicion, particularly in patients with
bilateral extensive bronchiectasis, by CF genotyping. Only six
patients had CF and were excluded.
Data regarding microbiology were obtained. All patients had at
least two samples of sputum examined. Patients for whom there
was a strong clinical suspicion of mycobacterial disease by the
clinician, but who had sputum that was negative, underwent
bronchoscopy. Only patients with a positive sputum or bronch-
oalveolar lavage (BAL) that showed growth of mycobacteria were
classiﬁed as having NTM.306  patients with the ICD -9 code 494
35
83 patients 
eval
Figure 1. Study ﬂowchart of non-tuberculous mycobacterial dThe following data were collected for patients included in this
study: (1) demographics including age, sex, race, height, weight,
and body mass index (BMI), (2) date of onset of symptoms and the
date when the patient was diagnosed with NTM, as well as the
method used for the diagnosis, (3) characteristics of the symptoms
including cough, sputum production, hemoptysis, dyspnea, and
weight loss, and other symptoms if present were recorded, (4)
smoking habits including current smoking status and the number
of packs smoked, (5) history of recurrent childhood pulmonary
infections (3 times up to 18 years of age), (6) associated diseases
and family history of bronchiectasis, (7) investigations performed
to evaluate an etiology including serum immunoglobulins, nasal
biopsy for cilia, and other tests, (8) pulmonary function tests, (9)
radiology ﬁndings, including if the changes were localized or
bilateral, (10) sputum microbiology results, (11) bronchoscopy
results if a patient had undergone one, (12) therapies that the
patient was receiving including antibiotic usage, prednisone
courses, clearance devices, and hospitalization record. The interval
between the worsening of pulmonary symptoms as recorded from
the patient history and the diagnosis of NTM infection was
characterized as a delay in diagnosis. This study was reviewed and
approved by the ethics committees of the University of Illinois at
Chicago with an approval number 2006-0742.
2.1. Statistical analysis
Categorical variables were described as counts and percentages
or examined as predictors using the odds ratio (OR) and were
tested by the Chi-square test, or, if applicable, Fisher’s exact test.
Univariate analysis was used to compare differences in demo-
graphic and clinical variables between bronchiectasis patients
from whom NTM was isolated and non-NTM patients. Compar-
isons were unpaired, and all tests of signiﬁcance were two-tailed.
Continuous variables were compared using the Student’s t-test for
normally distributed variables and the Wilcoxon rank-sum test for
non-normally distributed variables. In order to examine risk
factors for NTM isolation, a stepwise logistic regression model was
used. The outcome variable was isolation of NTM from respiratory
secretions from sputum or BAL and other variables listed in Table 1
that were considered statistically signiﬁcant upon univariate
analysis (p < 0.10) or considered clinically relevant.
Results were reported as adjusted ORs with 95% conﬁdence
intervals (CI). The goodness-of-ﬁt of the ﬁnal model was examined
by the Hosmer–Lemeshow test. A non-signiﬁcant p-value implied
that the model adequately ﬁts the data. The Kaplan–Meier
estimate curve was used to determine the cumulative probability patient were  exclud ed with  age < 18 years
 did n ot me et th e radiolo gic criter ia of br onc hiect asis 
uated  by radiologist  and the stud y’s revi ewer. 
6 patients  were exclude d becaus e of CF 
182  patients  wer e included in th e study
isease in patients with non-cystic ﬁbrosis bronchiectasis.
Table 1
Characteristics of the 182 patients enrolled in the studya
Variable NTM patient,
n (%)
Non-NTM
patient,
n (%)
p-Value
Age >65 years 45 (66) 23 (46) 0.0150
Male 11 (16) 30 (34) 0.0120
Diagnosis delay >12 months 29 (45) 34 (42) 0.6870
Diagnosis delay >24 months 34 (53) 46 (56) 0.6600
BMI >30 kg/m2 3 (11.5) 34 (33) 0.4000
Sputum production 48 (72) 56 (65) 0.3530
Hemoptysis 20 (30) 17 (20) 0.1510
Cough 65 (97) 75 (87) 0.0470
Dyspnea 34 (51) 40 (47) 0.6030
Chest pain 2 (3) 4 (5) 0.4720a
Cancer 9 (17) 8 (10) 0.2160
GERD 7 (14) 6 (7) 0.2580
COPD 4 (8) 8 (10) 0.6690a
DM 1 (2) 7 (9) 0.1520a
Current smoker 3 (4) 12 (14) 0.3090a
Childhood pulmonary infection 24 (36.4) 23 (27) 0.2220
Pneumonia 22 (40) 23 (35.9) 0.6490
Family history of bronchiectasis 3 (4.4) 1 (1.1) 0.3200a
PFT obstructive defect 7 (39) 34 (51) 0.3740
PFT restrictive defect 4 (27) 23 (39) 0.5500a
Bronchiectasis seen in CXR 22 (33) 22 (26) 0.3490
IV antibiotic therapy 4 (6) 16 (18) 0.0290a
Clearance device 31 (46) 11 (12) <0.0001
Flutter valve used 29 (43) 2 (2.3) <0.0001a
Mortality 1 (2) 5 (6) 0.1610a
NTM, non-tuberculous mycobacteria; BMI, body mass index; GERD, gastroesopha-
geal reﬂux disease; COPD, chronic obstructive pulmonary disease; DM, diabetes
mellitus; PFT, pulmonary function tests; CXR, chest X-ray; IV, intravenous.
a Data are number (%) of patients.
bFisher’s exact test.
Table 2
Logistic regression analysis results for patients with bronchiectasis with and
without NTMa
Variables p-Value OR (95% CI)
Age >65 years 0.191 0.51 (0.186–1.399)
Female gender 0.051 3.828 (0.997–14.704)
Recurrent childhood
pulmonary infections
0.087 0.426 (0.160–1.132)
BMI 0.008 0.876 (0.795–0.966)
COPD 0.487 9.584 (0.128–2.662)
GERD 0.932 0.935 (0.195–4.478)
NTM, non-tuberculous mycobacteria; OR, odds ratio; CI, conﬁdence interval; BMI,
body mass index; COPD, chronic obstructive pulmonary disease; GERD, gastro-
esophageal reﬂux disease.
a Adjusted risk of NTM isolation in patients with non-cystic ﬁbrosis bronchiec-
tasis by: age >65 years, male gender, recurrent childhood pulmonary infections,
BMI, COPD, gastroesophageal reﬂux disease (GERD), p > 0.05 by Hosmer–
Lemeshow goodness-of-ﬁt test.
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for the two groups were compared using the log-rank test.
All data analyses were performed using SPSS for Windows,
version 17.0; two-tailed p-values were used and p-values <0.05
were considered to be statistically signiﬁcant.
3. Results
One hundred eighty-two patients diagnosed with non-CF
bronchiectasis were included. Table 1 shows the demographic,
clinical, and outcome characteristics of the study population.
The mean (standard deviation (SD)) age of patients with a
diagnosis of bronchiectasis was 64.5 (15.1) years. Of the 182
patients who were identiﬁed with a diagnosis of bronchiectasis,
mycobacterial culture was performed for 137 (75%) based on
symptoms compatible with mycobacterial diseases or a clinical
suspicion. NTM was isolated from sputum or BAL in 68 (37%)
patients. Mycobacterium avium complex (MAC) was isolated from
55 (81%), Mycobacterium chelonae from ﬁve (7%), Mycobacterium
kansasii from two (3%), and other NTM were isolated from six (9%)
patients. The diagnosis of bronchiectasis and isolation of NTM was
signiﬁcantly higher in female patients. This was further conﬁrmed
by logistic regression analysis (Table 2). Patients in whom NTM
was isolated also had medical histories signiﬁcant for previous
childhood infections (Table 2).
The mean (SD) of diagnosis delay per month was 44.95 (56.2).
Gram-negative rods (Enterobacteriaceae group and Pseudomonas
aeruginosa bacilli) were isolated from 22 patients (14%), of whom
17 (77%) had never been co-isolated NTM (p = 0.031). Forty-one
(23%) patients were hospitalized secondary to complications from
bronchiectasis, seven (10%) of whom were those with NTM (p =
0.002). Table 2 shows the multivariate model that accounted for
the possible confounding effect of several factors, for patients with
bronchiectasis with and without NTM.Our univariate analysis suggests that patients with bronchiec-
tasis and NTM complained of cough as a major symptom,
suggesting that the presence of NTM contributed to a worsening
of their symptoms. Interestingly, there was no signiﬁcant
difference in the lung function characteristics of patients with
bronchiectasis with and without NTM. There was also no
signiﬁcant difference in the presence of comorbidities such as
chronic obstructive pulmonary disease (COPD), gastroesophageal
reﬂux disease (GERD), diabetes mellitus (DM), cancer, or HIV in
patients with bronchiectasis with or without NTM. The univariate
analysis suggested that patients with bronchiectasis and NTM used
clearance devices more frequently, although there was no
difference in the rate of usage of antibiotics for respiratory
infections. Overall, seven patients with bronchiectasis during this
period underwent surgery, two of whom had NTM isolated and ﬁve
patients were from the non-NTM group. The surgical resection was
for hemoptysis in three patients and localized disease with
continuing symptoms in the remaining four. Five patients
underwent lobectomies, one had a pneumonectomy, and one
had a cavernostomy.
The American Thoracic Society (ATS) criteria for the diagnosis of
NTM disease were met by 55 (30%) patients. Of the patients from
whom NTM was isolated, 80% met the ATS criteria for NTM disease.
Table 3 depicts the data for patients who were culture-positive for
NTM with and without disease.
The probability of NTM isolation was signiﬁcantly higher in
elderly female patients with non-CF bronchiectasis (p = 0.04), as
shown in Figure 2. Moreover, the probability of NTM isolation was
signiﬁcantly higher in the female group with low BMI (p = 0.002),
as shown in Figure 3.
4. Discussion
This study indicates that NTM is common in non-CF bronchi-
ectasis patients. The frequency of NTM in our bronchiectasis
population was 37%, and 30% of these patients met the ATS criteria
for NTM disease. NTM is more frequently isolated from elderly
female patients (age >65 years). In addition, our data suggest that
childhood pulmonary infection is a signiﬁcant risk factor for
acquiring NTM later in life. Furthermore, MAC is the most common
isolate (88%) of NTM in patients with bronchiectasis.
NTM have emerged over the past two decades as important
pathogens in patients with chronic lung diseases, including
patients with CF and patients with non-CF bronchiectasis. The
exact prevalence of NTM disease in patients with non-CF
bronchiectasis remains to be determined. It is also unclear if the
presence of NTM contributes to the pathogenesis of the underlying
disease process in patients with non-CF bronchiectasis. Previous
Table 3
Characteristics of the patients culture-positive for an NTM with and without
disease, based on ATSa
Variable NTM disease,
n (%)
Non-NTM
disease,
n (%)
p-Value
Age >65 years 26 (65) 19 (68) 0.806
Female 38 (95) 19 (68) 0.008
Diagnosis delay >12 months 19 (53) 16 (57) 0.728
Diagnosis delay >24 months 18 (50) 16 (57) 0.570
BMI >30 kg/m2 3 (10) 0 (0) 1.000a
Sputum production 26 (67) 22 (79) 0.290
Hemoptysis 12 (31) 8 (29) 0.846
Cough 39 (100) 26 (93) 0.900
Dyspnea 23 (59) 11 (39) 0.114
Chest pain 1 (3) 1 (4) 1.000a
Cancer 6 (18) 3 (16) 1.000a
GERD 4 (12) 3 (16) 0.697a
COPD 3 (9) 1 (5) 1.000a
DM 0 (0) 1 (5) 0.373a
Current smoker 2 (4) 1 (4) 1.000a
Childhood pulmonary infection 15 (39) 9 (33) 0.670
Pneumonia 14 (41) 8 (38) 0.821
Family history of bronchiectasis 3 (8) 0 (0) 0.263a
PFT obstructive defect 5 (42) 2 (33) 1.000a
PFT restrictive defect 1 (13) 3 (43) 0.282a
Bronchiectasis seen in CXR 10 (45) 12 (44) 0.100
IV antibiotic therapy 1 (3) 3 (11) 0.298a
Clearance device 20 (50) 9 (32) 0.175
Flutter valve used 29 (43) 2 (2.3) 0.146
Mortality 0 (0) 1 (4) 0.406a
NTM, non-tuberculous mycobacteria; ATS, American Thoracic Society; BMI, body
mass index; GERD, gastroesophageal reﬂux disease; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; PFT, pulmonary function testing; CXR,
chest X-ray; IV, intravenous.
a Data are number (%) of patients.
bFisher’s exact test.
Figure 2. The Kaplan–Meier estimate curve for the cumulative probability of NTM
isolation according to age and sex in patients with non-cystic ﬁbrosis
bronchiectasis.
Figure 3. The Kaplan–Meier estimate curve for the cumulative probability of NTM
isolation according to body mass index (BMI) and sex in patients with non-cystic
ﬁbrosis bronchiectasis.
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patients, although the reasons for this increased susceptibility of
elderly women to NTM is unclear and needs further investiga-
tion.5,11 Tanaka and colleagues, reported that 34–50% of bronchi-
ectasis patients have active NTM pulmonary infection, especially
MAC infection.9 Wickremasinghe and researchers also found MAC
to be the predominant NTM species isolated in 72% of sputum
samples obtained from their study population of patients with
non-CF bronchiectasis.11 These results are consistent with those of
our study in which MAC was the leading pathogen isolated from
samples obtained from patients with non-CF bronchiectasis. It is
likely that structural changes in the airways that cause alterations
in mucociliary clearance with an increase in mucus production
predispose patients with bronchiectasis to NTM colonization and
subsequent infection.13,14 However, it is also plausible that
primary alteration in the immune response in patients with
non-CF bronchiectasis may also play a pivotal role in the
development of NTM infections.15
Although the predisposition of elderly women to disease due
to MAC has been described, our data suggest that male gender
may partially protect from the acquisition of NTM.12 Gender
differences in the predisposition to NTM have previously been
noted, however the mechanisms  of the causality are specula-
tive. A study by Han and colleagues showed that MAC infections
in general are rare in women younger than 50 years, and as the
number of postmenopausal years increases, the prevalence rate
of MAC increases as well. As a result, with menopausal status
playing a role in MAC infection, Han and colleagues hypothe-
sized that estrogen has a protective effect on MAC.16 There are
some additional supporting data for this speculation. The serum
levels of macrophage colony-stimulating factor fall during the
ﬁrst 10 years of menopause, which is restored with hormonereplacement.17 In addition, it has been shown that estrogen
protects mice from MAC infection, mainly through augmenting
macrophage functions.18 In contrast, Yamamoto et al. showed
that testosterone increases susceptibility to NTM in mice.19
Cooper et al. showed that the use of anabolic steroids is
associated with an increase in mycobacterial infections.20
Therefore, it appears that there might be other reasons to
justify the gender difference in NTM diseases other than sexual
hormones. It is plausible that a genetic resistance in males may
play a role. Nonetheless, further studies to deﬁne the mecha-
nisms that are responsible for these differences are clearly
needed.
The Kaplan–Meier curve showed that the probability of NTM
isolation was signiﬁcantly higher in patients with a low BMI. Our
study results are in agreement with those of Kim and colleagues
who found that patients with NTM infections have a distinct body
morphology.21 Ziedalski and colleagues also reported low BMI
values in their patients with pulmonary NTM infections.22
The results of our study showed that there is a long NTM
diagnostic delay in bronchiectasis patients. We speculate that the
absence of a pathognomonic clinical picture, coupled with variable
radiologic presentation of ﬁndings of NTM disease in the presence
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diagnosis and treatment. Previous studies have reported that
patients who have a delay in diagnosis of NTM have a higher rate of
recurrence.23 Because of the retrospective design of our study,
there is a recall bias in determining the accurate diagnostic delay.
Future studies with larger numbers of patients are needed to better
evaluate the extent of the association of bronchiectasis with NTM
disease, the delay in diagnosis, and to identify associated risk
factors.
Our study suggests that a signiﬁcant number of patients
with non-CF bronchiectasis were positive for the isolation of
atypical mycobacteria from their sputum. However, further
studies are needed to establish whether the presence of NTM
infection has an impact on the clinical outcomes of patients
with bronchiectasis. The relatively small cohort size of the
present study did not allow for this analysis. This study was
unable to show any possible association between NTM
infection and DM, probably due to the sample size. Therefore,
understanding the relationship between NTM infection and DM
will require further studies.
This study has several other limitations that should be noted.
First, the study population was entered from a single tertiary
referral center and, therefore, had multiple risk factors for NTM
infection. Secondly, data regarding the use of macrolide therapy
were not collected in our study; patients without NTM may have
received macrolide therapy which may have led to partial
treatment and misclassiﬁcation. Third, the investigation to
diagnose CF was not performed in all patients and there was
no documentation of a family history of CF. Therefore patients
with heterozygotic status for CF as non-CF may have been
misclassiﬁed.
In summary, this study shows that NTM is commonly isolated
from patients with non-CF bronchiectasis. Additionally MAC
appears to be the most common pulmonary NTM in this group.
This study also shows that elderly females, particularly those with
low BMIs, are at a higher risk for acquiring NTM diseases. A better
understanding of the role of NTM in the outcomes of patients with
bronchiectasis may generate new therapeutic modalities for
patients with severe disease. Furthermore, during the initial
assessment of patients with bronchiectasis, physicians might need
to consider sputum culture, and possibly bronchoscopy, if the
pulmonary imaging study is suggestive of NTM, as a predictive
factor for clinical outcomes.
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